NK 611 HCl

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 584811

CAS#: 105760-98-3 (HCl)

Description: NK 611 HCl is a new semisynthetic analogue of etoposide and has been found to be more potent against several cancer cell lines in vitro than etoposide.

Chemical Structure

img
NK 611 HCl
CAS# 105760-98-3 (HCl)
Instruction

Theoretical Analysis

MedKoo Cat#: 584811
Name: NK 611 HCl
CAS#: 105760-98-3 (HCl)
Chemical Formula: C31H38ClNO12
Exact Mass: 651.21
Molecular Weight: 652.090
Elemental Analysis: C, 57.10; H, 5.87; Cl, 5.44; N, 2.15; O, 29.44

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Related CAS #: 105655-99-0 (free acid); 105760-98-3 (HCl)  

Synonym: NK 611; NK-611; NK611; NK 611 HCl

IUPAC/Chemical Name: Furo(3',4':6,7)naphtho(2,3-d)-1,3-dioxol-6(5aH)-one, 9-((2-deoxy-2-(dimethylamino)-4,6-O-ethylidene-beta-D-glucopyranosyl)oxy)-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,5-dimethoxyphenyl)-, hydrochloride, (5R-(5alpha,5abeta,8aalpha,9beta))-

InChi Key: PYLTTZZOZBYUEI-DZMPZKOJSA-N

InChi Code: InChI=1S/C31H37NO12.ClH/c1-13-38-11-22-29(42-13)27(34)25(32(2)3)31(43-22)44-28-16-9-19-18(40-12-41-19)8-15(16)23(24-17(28)10-39-30(24)35)14-6-20(36-4)26(33)21(7-14)37-5;/h6-9,13,17,22-25,27-29,31,33-34H,10-12H2,1-5H3;1H/t13?,17-,22+,23-,24-,25+,27+,28+,29+,31-;/m0./s1

SMILES Code: O=C1OC[C@]2([H])[C@H](O[C@H]3[C@H](N(C)C)[C@H]([C@@H]([C@@H](CO4)O3)OC4C)O)C5=C(C=C6OCOC6=C5)[C@H](C7=CC(OC)=C(O)C(OC)=C7)[C@]21[H].[H]Cl

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >3 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 652.09 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Hanauske AR, Wüster KC, Lehmer A, Rotter M, Schneider P, Kaeser-Fröhlich A, Rastetter J, Depenbrock H. Activity of NK 611, a new epipodophyllotoxin derivative, against colony forming units from freshly explanted human tumours in vitro. Eur J Cancer. 1995 Sep;31A(10):1677-81. PubMed PMID: 7488424.

2: Hüttmann A, Mross K, Hossfeld DK. Determination of the new podophyllotoxin derivative NK 611 in plasma by high-performance liquid chromatography with ultraviolet detection. J Chromatogr. 1993 Oct 29;620(2):233-8. PubMed PMID: 8300791.

3: Mross K, Hüttmann A, Herbst K, Hanauske AR, Schilling T, Manegold C, Burk K, Hossfeld DK. Pharmacokinetics and pharmacodynamics of the new podophyllotoxin derivative NK 611. A study by the AIO groups PHASE-I and APOH. Cancer Chemother Pharmacol. 1996;38(3):217-24. PubMed PMID: 8646795.

4: Daley L, Guminski Y, Demerseman P, Kruczynski A, Etiévant C, Imbert T, Hill BT, Monneret C. Synthesis and antitumor activity of new glycosides of epipodophyllotoxin, analogues of etoposide, and NK 611. J Med Chem. 1998 Nov 5;41(23):4475-85. PubMed PMID: 9804687.

5: Takigawa N, Ohnoshi T, Ueoka H, Kiura K, Moritaka T, Tabata M, Segawa Y, Shibayama T, Gemba K, Matsumura T, et al. [In vitro comparison of podophyllotoxin analogues; etoposide, teniposide and NK 611 using human lung cancer cell lines]. Gan To Kagaku Ryoho. 1993 Mar;20(4):473-7. Japanese. PubMed PMID: 8383949.

6: Capranico G, Giaccone G, Zunino F, Garattini S, D'Incalci M. DNA topoisomerase II poisons and inhibitors. Cancer Chemother Biol Response Modif. 1997;17:114-31. Review. PubMed PMID: 9551211.

7: Rassmann I, Thödtmann R, Mross M, Hüttmann A, Berdel WE, Manegold C, Fiebig HH, Kaeser-Fröhlich A, Burk K, Hanauske AR. Phase I clinical and pharmacokinetic trial of the podophyllotoxin derivative NK611 administered as intravenous short infusion. Invest New Drugs. 1998-1999;16(4):319-24. PubMed PMID: 10426664.

8: Pagani O, Zucchetti M, Sessa C, de Jong J, D'Incalci M, De Fusco M, Kaeser-Fröhlich A, Hanauske A, Cavalli F. Clinical and pharmacokinetic study of oral NK611, a new podophyllotoxin derivative. Cancer Chemother Pharmacol. 1996;38(6):541-7. PubMed PMID: 8823496.

9: De Fusco M, D'Incalci M, Gentili D, Reichert S, Zucchetti M. High-performance liquid chromatographic assay for the determination of the novel etoposide derivative dimethylaminoetoposide (NK611) and its metabolites in urine of cancer patients. J Chromatogr B Biomed Appl. 1995 Feb 17;664(2):409-14. PubMed PMID: 7780594.

10: Machida M, Tanaka S, Nakamori K. Simultaneous determination of NK611, a novel water-soluble derivative of etoposide, and its metabolite (DeNK611) in dog plasma by column-switching high performance liquid chromatography. Biomed Chromatogr. 1993 Mar-Apr;7(2):82-5. PubMed PMID: 8485379.

11: Rassmann I, Schrödel H, Schilling T, Zucchetti M, Kaeser-Fröhlich A, Rastetter J, Hanauske AR. Clinical and pharmacokinetic phase I trial of oral dimethylaminoetoposide (NK611) administered for 21 days every 35 days. Invest New Drugs. 1996;14(4):379-86. PubMed PMID: 9157073.

12: Zucchetti M, De Fusco M, Sessa C, Fröhlich A, Reichert S, D'Incalci M. High-performance liquid chromatographic assay for the determination of the novel podophyllotoxin derivative dimethylaminoetoposide (NK611) in human plasma. J Chromatogr B Biomed Appl. 1994 Mar 18;654(1):97-102. PubMed PMID: 8004249.